Qingtian Ma

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer.⚑
  2022 L1 45/100 ⚑

1 assessed by us (0 reproduced) · 26 not yet assessed — every PubMed paper on record, linked below.

• Correction: Targeting SOST using a small‑molecule compound retards breast cancer bone metastasis ↗

  Molecular Cancer · 2025 · PMID 40241133
  not yet assessed
• Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway ↗

  Science China Life Sciences · 2025 · PMID 40549239
  not yet assessed
• Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer ↗

  eLife · 2025 · PMID 40338227
  not yet assessed
• Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903] ↗

  Drug Resistance Updates · 2025 · PMID 40912935
  not yet assessed
• Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis ↗

  eLife · 2025 · PMID 40928840
  not yet assessed
• <i>CEMIP</i> as a potential biomarker and therapeutic target for breast cancer patients: Erratum ↗

  International Journal of Medical Sciences · 2025 · PMID 41049451
  not yet assessed
• Polyphenol nanocomplex modulates lactate metabolic reprogramming and elicits immune responses to enhance cancer therapeutic effect ↗

  Drug Resistance Updates · 2024 · PMID 38309140
  not yet assessed
• KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer ↗

  Nature Communications · 2023 · PMID 37147285
  not yet assessed
• FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway ↗

  Science China Life Sciences · 2023 · PMID 37460715
  not yet assessed
• KCNJ15 deficiency promotes drug resistance via affecting the function of lysosomes ↗

  Asian Journal of Pharmaceutical Sciences · 2023 · PMID 37274925
  not yet assessed
• KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer ↗

  Figshare · 2023
  not yet assessed
• Targeting SOST using a small-molecule compound retards breast cancer bone metastasis ↗

  Molecular Cancer · 2022 · PMID 36581888
  not yet assessed
• A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells ↗

  Drug Resistance Updates · 2022 · PMID 36463808
  not yet assessed
• NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer⚑

  Frontiers in Pharmacology · 2022 · PMID 35431924
  L1 45/100 ⚑
• Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer ↗

  eLife · 2022 · PMID 36602226
  not yet assessed
• <i>CEMIP</i> as a potential biomarker and therapeutic target for breast cancer patients ↗

  International Journal of Medical Sciences · 2022 · PMID 35370456
  not yet assessed
• Author response: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer ↗

  2022
  not yet assessed
• Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2 ⁺ HR ⁺ Breast Cancer ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2022
  not yet assessed
• Long-Term Outcomes by Neoadjuvant Efficacy Indexes in Patients with HR and HR /HER2 Breast Cancer after Neoadjuvant Systemic Therapy: A Systematic Review and Meta-Analysis ↗

  SSRN Electronic Journal · 2022
  not yet assessed
• Author response: Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer ↗

  2022
  not yet assessed
• Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis ↗

  eLife · 2021 · PMID 34318746
  not yet assessed
• Dalpiciclib and Pyrotinib Exert Synergistic Antitumor Effects in Triple Positive Breast Cancer ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2021
  not yet assessed
• Author response: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis ↗

  2021
  not yet assessed
• <i>HCK</i> can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients ↗

  International Journal of Medical Sciences · 2020 · PMID 33162805
  not yet assessed
• The dynamical environment of the primary in the triple asteroid (45) Eugenia ↗

  Open Astronomy · 2020
  not yet assessed
• Association of CD44 ⁻ /CD24 ⁻ Breast Cancer Cells with Late Stage Tumor Recurrence ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2020
  not yet assessed
• Energy-Efficient Opportunistic Transmission Scheduling for Sparse Sensor Networks with Mobile Relays ↗

  Mathematical Problems in Engineering · 2016
  not yet assessed